Navigation Links
Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting

t treatment with these or other agents associated with myopathy should weigh carefully the potential benefits and risks and should monitor and advise patients to report any signs or symptoms of unexplained muscle pain, tenderness or weakness, particularly during periods of upward dosage titration. TYZEKA therapy should be interrupted if myopathy is suspected, and discontinued if myopathy is diagnosed. -- Because TYZEKA is eliminated primarily by renal excretion, co- administration of TYZEKA with drugs that affect renal function may alter plasma concentrations of TYZEKA and/or the coadministered drug. Dose interval adjustment is required in patients with creatinine clearance <50mL/min including those with end stage renal disease on hemodialysis. For patients on hemodialysis, telbivudine should be administered after hemodialysis. -- The safety and efficacy of TYZEKA in liver transplant recipients are unknown. If TYZEKA treatment is determined to be necessary for a liver transplant recipient who has received or is receiving an immunosuppressant that may affect renal function, such as cyclosporine or tacrolimus, renal function should be monitored both before and during treatment with TYZEKA. -- Patients should be advised that treatment with TYZEKA has not been shown to reduce the risk of transmission of HBV to others through sexual contact or blood contamination. -- Safety and effectiveness of TYZEKA in pediatric patients under the age of 16 years have not been established. -- Most common adverse events (>5%) in clinical studies, regardless of attributability to telbivudine, were upper respiratory tract infection (14%), fatigue and malaise (12%), abdominal pain (12%), nasopharyngitis (11%), headache (11%), blood CPK increased (9%), cough (7%), nausea and vo
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/3/2015)... Research and Markets ... the "Global Craniomaxillofacial (CMF) Devices Market 2015-2019" ... global craniomaxillofacial devices market to grow at a ... covers the present and future scenario of the ... the market size, we use revenues generated from ...
(Date:9/3/2015)... , Sept. 3, 2015 HeartWare ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that its President and Chief Executive Officer, ... 2015 Wells Fargo Healthcare Conference at 8:50 a.m. ET ... Sept. 9-10, 2015 at The Hyatt Regency, ...
(Date:9/3/2015)... DUBLIN , Sept. 3, 2015 Research ... of the "Investigation Report on China Olmesartan Market, ... In 1991, olmesartan medoxomil was successfully developed by Sankyo ... In Apr. 2002, olmesartan medoxomil was approved by FDA ... now become the best- selling drug in the world ...
Breaking Medicine Technology:Global Craniomaxillofacial (CMF) Devices Market 2015-2019 - Product Innovation and Cost Reduction a Key Market Trend 2HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2China Olmesartan Investigation Market Report 2010-2019 2
... healthcare providers to have money in the bank -- ... incentive program -- are two Texas hospitals, Stamford (Texas) ... Both Stamford and Hemphill quickly moved from paper ... be among the initial 37 hospitals nationwide, including 13 ...
... ATLANTA, June 7, 2011 CardioMEMS, Inc ., an ... a proprietary wireless sensing and communication technology for the human ... Yadav, M.D. , is a finalist for the 25th annual ... Entrepreneur category. The awards are sponsored by the Metro Atlanta ...
Cached Medicine Technology:Two Texas Hospitals Leverage Prognosis EHR to Meet Meaningful Use Requirements and Receive ARRA Incentive Funds 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Selected as a Finalist for 2011 Business Person of the Year Award 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Selected as a Finalist for 2011 Business Person of the Year Award 3
(Date:9/3/2015)... Lawrenceville, Georgia (PRWEB) , ... September 03, 2015 ... ... the spread of disease in Haiti, has partnered with Slingshot® Product Development Group ... no electricity or running water. Michael Wahl with DriButts plans to bring 600 ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Spouse/Caregiver Scholarship applications are open for spring 2016. Scholarships are awarded two times ... Hope For The Warriors® is a national nonprofit dedicated to restoring a sense ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... announces the release of her debut book, “Stop Wasting Your Time Blaming Others ... Day (September 6), Hartley’s guide to overcoming life’s obstacles by taking full responsibility ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... comprehensive eating disorder treatment for adults and adolescents struggling with anorexia, bulimia, ... has joined the medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu ...
(Date:9/3/2015)... ... 2015 , ... As a result of the Patient Protection ... insurance plans, more employers are moving to a self-funded model for pharmacy plans, ... United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s largest ...
Breaking Medicine News(10 mins):Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... a study published in the August issue of The ... methicillin-resistant Staphylococcus aureus (MRSA) to be// the most common ... across the nation. Many patients presenting to the ... found to be having MRSA infection that was resistant ...
... that Autism could affect the entire brain, not just ... it had been once thought.// ,A new ... (CPEA) has shown that autism affects a wide range ... researchers have explained that their study seemingly suggests that ...
... Health Information to examine the work practices of family ... are providing obstetrical care compared with 10 years ago ... patients remains high. ,Family physician's fee-for-service data ... was examined in the study done by the Ottawa-based ...
... Canberra claim that they may have mastered the art ... ,Positive parenting program was developed 2 years ago by ... intention to make parenting more pleasant. Minimizing stress and ... the aim. Researcher, Penny Sellers, who will develop it ...
... throne has extended his generosity and assistance to revive the ... measures to get back the lost splendour. ,The Prince ... London residence, to launch an international campaign to restore the ... palaces and temples built by Nepal's Malla kings, who ruled ...
... procedures like angioplasty are the various treatments for ... ,Elyria is a small industrial city in northeast ... in the country, would suggest their patients to ... threading balloon catheters through arteries and sometimes placing ...
Cached Medicine News:Health News:Community-associated MRSA: Most Common Cause Of Skin Infection 2Health News:Community-associated MRSA: Most Common Cause Of Skin Infection 3Health News:Effects Of Autism On Brain Much Wider Than Presumed 2Health News:Parenting skills to manage bad behaviour 2Health News:A Princely Assistance to the Nepal Heritage 2Health News:Heart Procedure numbers go haywire in an Ohio City 2
Nebulizer Custom Kit...
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... achieves optimum lung penetration for maximum therapeutic ... 1.04-1.10 µ at 6-8 LPM. Latex-free components. ... ,As the world leader in airway management ... of proven technology by offering top brands ...
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
Medicine Products: